Celsion (CLSN) +3.6% premarket after CEO Michael Tardugno tells Reuters his company has a $1B cancer therapy with its ThermoDox treatment for liver cancer. CLSN, with a market cap of only ~$73M and just 16 employees, aims to place an old cancer drug into a new delivery method and adding heat in a recipe for success that can address a large unmet need in cancer.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/